Dementia Matters26 Apr 2024

Making an IMPACT: Advancing Alzheimer’s Disease Clinical Trials Through Workforce Development and Inclusivity

Advances in Alzheimer’s disease clinical trials are accelerating rapidly, leading to new insights and disease-modifying therapies, but how does the field continue bolstering that momentum? For Dr. Rema Raman, it’s through improving inclusivity and training for early-career researchers. Recorded at the 2024 Alzheimer’s Disease & Related Dementias Research Day, Dr. Raman joins the podcast to discuss her work in research recruitment and retention, the importance of training the next generation of clinical trialists in dementia research with the IMPACT-AD program and more from her featured presentation.

Guest: Rema Raman, PhD, co-director, Institute of Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD), director, section of biostatistics, section of participant recruitment & retention section, Alzheimer’s Therapeutic Research Institute, professor of neurology, University of Southern California

Show Notes

Watch our YouTube page for upcoming recordings of Dr. Raman’s presentation and other featured speakers at Alzheimer’s Disease & Related Dementias Research Day 2024.

Learn more about Alzheimer’s Disease & Related Dementias Research Day on our website.

Learn more about the Institute of Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) on their website.

Learn more about Dr. Raman at her bio on the Keck School of Medicine website.

Connect with us

Find transcripts and more at our website.

Email Dementia Matters: dementiamatters@medicine.wisc.edu

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(244)

New Alzheimer’s Association Special Report Breaks Down How Americans Understand and Support their Brain Health

In recent years, public interest in brain health has increased. So how are Americans understanding brain health information and incorporating it into their own lives? This year, the Alzheimer’s Associ...

25 Aug 37min

Reflecting on 25 Years of the Wisconsin Registry for Alzheimer’s Prevention

Twenty-five years ago, a single participant enrolled in what would become the Wisconsin Registry for Alzheimer's Prevention (WRAP), now one of the largest and longest-running studies of Alzheimer's ri...

12 Aug 35min

How Dementia Caregiving Affects the Spousal Caregiver

Caring for those with dementia represents a major public health challenge, with caregivers, especially spouses, providing long-term, largely unpaid care. With caregiving stress linked to a decline in ...

28 Jul 39min

Managing the Medicine Cabinet: How Prescriptions Impact Cognition and Brain Health as We Age

Prescription medications, over-the-counter drugs and supplements are incredibly common among older adults, yet many of these routine treatments can unexpectedly impact cognitive function and brain hea...

14 Jul 35min

Taking a Deep Dive into Subjective Cognitive Decline

Dr. Jessen returns to the podcast to take a deeper dive into subjective cognitive decline (SCD). Aiming to cover everything relating to SCD, Dr. Jessen shares insights in prognosis, risk factors and h...

7 Jul 17min

Defining Subjective Cognitive Decline

Subjective cognitive decline (SCD) can be one of the earliest noticeable signs of Alzheimer's disease, yet SCD is not yet fully understood. To help us understand more, Dr. Frank Jessen, an expert in t...

30 Jun 30min

SPRINT to a Healthy Mind: How Blood Pressure Control Affects Brain Health and Dementia Risk

Geriatrician Dr. Mark Supiano joins the podcast to discuss the connection between heart and brain health. Citing multiple clinical trials, he breaks down what these studies and their findings mean for...

18 Jun 40min

Addressing Cochrane’s Review on Amyloid-Targeting Treatments for Alzheimer’s Disease

Amyloid-targeting monoclonal antibody treatments have ushered in a new era of Alzheimer’s disease therapies after decades of research and clinical trials. A recent review published by Cochrane, a glob...

4 Jun 44min